Related Experiment Videos
The effect of bromocriptine on circulating vasopressin
Clinical Science (London, England : 1979)
|October 1, 1982
Summary
Bromoergocriptine, a dopamine agonist, increased plasma levels of arginine vasopressin (AVP) in humans. This suggests that dopamine plays a role in regulating AVP release in response to osmotic changes.
Area of Science:
- Neuroendocrinology
- Human Physiology
Background:
- Arginine vasopressin (AVP) is a key hormone regulating water balance.
- The release of AVP is known to be influenced by osmotic stimuli.
- The role of dopaminergic pathways in AVP regulation requires further elucidation.
Purpose of the Study:
- To investigate the effect of a dopamine agonist on osmotically stimulated AVP release in humans.
- To explore the potential dopaminergic control of AVP secretion.
Main Methods:
- Oral administration of bromoergocriptine (2.5 mg), a dopamine agonist.
- Measurement of plasma [arginine]vasopressin ([Arg]VP) concentrations.
- Assessment of osmotic stimulation in five healthy human subjects.
Main Results:
- Bromoergocriptine administration enhanced the osmotically stimulated increase in plasma [Arg]VP concentrations.
- A statistically significant rise in [Arg]VP was observed post-administration.
Conclusions:
- The findings support the hypothesis that dopaminergic pathways modulate the osmotically induced release of [Arg]VP in humans.
- Dopamine agonists may influence the regulation of water homeostasis via AVP.